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BACKGROUND Most inappropriate shocks from the subcutaneous
implantable cardioverter-deﬁbrillator (S-ICD) are caused by cardiac
oversensing. A novel sensing methodology, SMART Pass (SP; Boston
Scientiﬁc Corporation, Natick, MA), aims to reduce cardiac over-
sensing.
OBJECTIVE The purpose of this study was to evaluate the effect of
SP on shocks in ambulatory S-ICD patientsQ5 .
METHODS Patients implanted in 2015–2016 and enrolled in a
remote patient monitoring system were included and followed for
1 year. Shocks were adjudicated by 3 independent blinded reviewers
as appropriate or inappropriate. Shock incidence was calculated for
patients with SP programmed enabled or disabled at implantation,
censoring patients when SP programming changed or at the last
transmission. The SP setting (enabled vs disabled) was modeled
as a time-dependent Cox regression variable.
RESULTS The cohort consisted of 1984 patients, and a total of 880
shocks were adjudicated. At implantation, SP was enabled in 655
patients (33%) and disabled in 1329 patients (67%). SP reduced
the risk for the ﬁrst inappropriate shock by 50% (P , .001) and
the risk for all inappropriate shocks by 68% (P, .001) in multivar-
iate analysis adjusted for age and device programming. The inci-
dence of inappropriate shocks was 4.3% in the SP enabled arm vs
9.7% in the SP disabled arm. The incidence of appropriate shocks
was similar (5.2% vs 6.6%; P 5 .18) along with the time to treat
the ﬁrst appropriate shock (17.4 seconds vs 16.7 seconds;
P 5 .92) for SP enabled vs disabled, respectively.
CONCLUSION This prospective blinded evaluation of the SP ﬁlter
demonstrates that enabling the SP ﬁlter results in a signiﬁcant
reduction of inappropriate shocks by the S-ICD without a negative
effect on appropriate shocks.
KEYWORDS Appropriate shocks; Inappropriate shocks; Subcutane-
ous ICD Q6
(Heart Rhythm 2018;-:1–8) © 2018 The Authors. Published by
Elsevier Inc. on behalf of Heart Rhythm Society. This is an open ac-
cess article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The implantable cardioverter-deﬁbrillator (ICD) is an estab-
lished therapy to prevent sudden cardiac death.1,2 Despite the
effectiveness in reducing arrhythmic mortality, conventional
ICD systems have been associated with morbidity because of
short- and long-term complications with endovascular
leads.3–5 To address these complications, an entirely
subcutaneous implantable cardioverter-deﬁbrillator (S-ICD)
system was developed with no leads within or on the heart.6
Several studies have demonstrated the feasibility and safety
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of the S-ICD system in detecting and terminating life-
threatening ventricular arrhythmias.7–9 Despite the safety and
efﬁcacy of the S-ICD system, the main cause of morbidity in
S-ICD patients is the inappropriate shock, primarily caused
by cardiac oversensing.10,11 An initial update in the
morphology-based sensing algorithm in the S-ICD reduced
inappropriate chargesQ7 because of T-wave oversensing by
w40%.12 In order to reduce inappropriate shocks further, a
new high-pass ﬁlter (SMART Pass [SP], Boston Scientiﬁc
Corporation, Natick, MA) available within the S-ICD system
was activated for cardiac sensing.
We evaluated the effect of SP on shocks in ambulatory
S-ICD patients. For the purpose of this study, events in
S-ICD patients enrolled in the LATITUDE remote follow-up
system (Boston Scientiﬁc) were used in order to allow real-
life events to be evaluated.
Methods
Study design
The LATITUDE remote patient monitoring system was mar-
ket released in February 2006 for CRT-D and ICD devices. In
2015, the EMBLEM S-ICD system (Boston Scientiﬁc) was
added to the LATITUDE network system. Device data are
transmitted wirelessly from the implanted device to a central
server via interaction with the LATITUDE communicator in
the patient’s home. Data are available through a secured web-
site for review by the patient’s health care providerQ8 . Partici-
pating centers are engaged in a data processor agreement
that governs the use of LATITUDE data, and each patient
signed a data authorization form that allows the use of anon-
ymous data for research purposes. The study cohort consisted
of patients who received an S-ICD between January 2015 and
December 2016Q9 . For the purpose of the study, patients had to
be enrolled in the European LATITUDE remote monitoring
system. LATITUDE allows for limited demographic data,
and as such, this study design focuses on events as it relates
to programming.
The SP ﬁlter was approved on April 20, 2016, with CE
Mark approval of the EMBLEM MRI (model A219) device,
and the ﬁrst implantation occurred on April 25, 2016. The SP
ﬁlter was retroactively available for A209 devices through a
ﬁrmware upgrade. The SP ﬁlter could be programmed active
following the device setup process and selection of the
optimal sensing vector.
Sensing of the S-ICD system and SP
The S-ICD system uses 3 sensing electrodes to record cardiac
electrical activity: (A) superior to the sternal deﬁbrillation
coil; (B) inferior to the sternal deﬁbrillation coil; and (C) pulse
generator (CAN) implanted left-lateralQ10 at the midaxillary line.
These electrodes represent 3 vector projections of cardiac
electrical conduction, which resembles the signal characteris-
tics of the standard surface electrocardiogram (ECG): pri-
mary, B to CAN; secondary, A to CAN; alternate, A to B.
One of the 3 available vectors is selected (on the basis of
the optimal QRS-to-T wave ratio) for use as a conﬁguration
for sensing. Each detected cardiac signal is sent through
several noise detection and 4 double detection algorithms to
determine whether oversensing is present.
Two generations of the S-ICD system—EMBLEM A209
and EMBLEM-MRI A219—can apply an additional high-
pass ﬁlter to the sensing methodology, SP, in order to reduce
inappropriate therapy Q11. SP enables the high-pass ﬁlter for car-
diac sensing only while continuing to use the wide-band
ECG for rhythm discrimination purposes (Figure 1). The
high-pass ﬁlter is activated if the sense vector signal character-
isticallymeets theminimal QRS amplitude requirement (0.5
mV). The activated ﬁlter is a ﬁrst-order high-pass ﬁlter with
corner frequency between 8 and 9 Hz and a roll-off rate of
20 dB/decade Q12. Such a ﬁlter allowsmaximum reduction around
the corner frequency and a gradual reduction at lower fre-
quencies, thereby not affecting signals at higher frequencies
(.10 Hz). Based on the fundamental frequency of T waves
(,9 Hz) and QRS complexes (.10 Hz) observed on surface
and subcutaneous electrocardiograms (S-ECGs), SP is more
likely to reducemost Twaveswhile allowing accurate sensing
of the QRS complex owing to the improved QRS-to-T wave
ratio.13 In an effort to avoid undersensing of low-amplitude
ventricular arrhythmias, SP is speciﬁcally designed to auto
deactivate in the presence of low-amplitude signals (0.25
mV, SP ﬁltered), whether cardiac or noncardiac.
Event adjudication
Before adjudication, all device-stored events were de-identiﬁed
of patient data and reviewers were blinded to the SP setting
(enabled vs disabled). The event adjudication committee
composed of 3 investigators experienced in S-ICD and
S-ECG interpretation. Two investigators (D.A.M.J.T. and
T.F.B.) reviewed the events independently. In case of discor-
dance, the third investigator (V.A.) was consulted to reclassify
the event and provide a ﬁnal decision.
Categories for rhythm classiﬁcation were polymorphic
ventricular tachycardia (PVT)/ventricular ﬁbrillation (VF),
monomorphic ventricular tachycardia (MVT), normal sinus
rhythm, sinus tachycardia (ST), atrial ﬁbrillation (AF), and
supraventricular tachycardia (SVT). Shocks delivered for
PVT/VF or MVT above the programmed detection rate
were classiﬁed as appropriate. Shocks delivered for all other
rhythms were classiﬁed as inappropriate, including PVT and
MVT below the lowest programmed detection rate with over-
sensing. Reviewers applied standard deﬁnitions for ventricu-
lar arrhythmias: (1) MVT was deﬁned as stable single QRS
morphology from beat to beat; (2) PVTwas deﬁned as chang-
ing or multiform QRS morphology from beat to beat; and (3)
VF was deﬁned as a rapid irregular ventricular activity with
marked variability in waveforms, usually with a ventricular
rate of .300 betas/min. To assess the interobserver vari-
ability, the Cohen’s k statistic and percent agreement
between reviewers were calculated.
Therapy characteristics were also evaluated. Time to ther-
apy was deﬁned as the interval from the onset of the
arrhythmia until delivery of the ﬁrst shock using the stored
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S-ECG of the device. First shock efﬁcacywas deﬁned as con-
version of the ventricular arrhythmia, PVT/VF or MVT,
before the start of a second charge.
Statistical analysis
All analyses were performed using R version 3.4.3Q13 . Normality
of distribution was determined using the Shapiro-Wilk test.
Continuous variables are presented as mean 6 SD or as me-
dian (interquartile range), where appropriate. Categorical
data are presented as count (percentage). A 2-sided indepen-
dent Student t test or Mann-Whitney U test was used to eval-
uate continuous variables and Fisher exact test for categorical
variables. The rhythm triggering the ﬁrst shock in an episode
was used for calculating the incidence of shocksQ14 . SP baseline
programmingwas evaluated on the day of implantation. As SP
can be programmed ON and OFFQ15 during follow-up, the SP
setting (enabled vs disabled) was modeled as a time-
dependent Cox regression variable to calculate the hazard ratio
(HR) with corresponding 95% conﬁdence interval (CI) for the
incidence of both the ﬁrst inappropriate shock and all inappro-
priate shocks (recurrent event analysis), adjusting for age and
programming of detection zones. The Kaplan-Meier method
was used to estimate the cumulative incidence of events at
1-year follow-up with censoring at the end of follow-up, as
well as separately by censoring at programming change (as
programmed). Differences between groups were
Q1
compared
using the log-rank test. A P value of,.05 was considered sta-
tistically signiﬁcant.
Results
The study cohort consisted of 1984 patients; 655 patients
with SP enabled (33%) and 1329 with SP disabled (67%). Pa-
tient demographic characteristics and programming of the de-
vices are presented in Table 1. Most devices were
programmed with 2 zones, which provided morphology
discrimination for events with rates in the conditional zone.
There was no signiﬁcant difference in patients’ age, but the
programmed rate cutoffs were slightly different between pa-
tients with SP enabled and those with SP disabled.
Patients were followed for a mean of 1.46 0.5 years after
implantation. The mean follow-up period was shorter in the
SP enabled group than in the SP disabled group (1.1 6 0.3
years vs 1.6 6 0.5 years, respectively; P , .001). During
follow-up, 706 treated episodes with 880 shocks in 309 pa-
tients (16%) were recorded. Rhythm adjudication and appro-
priateness of shock therapy were available for 880 shocks.
The agreement between reviewers was 94.3%, with a Co-
hen’s k of 0.89. The adjudication results for the ﬁrst shock
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Figure 1 Signal processing of the EMBLEMS-ICD Q21with SMART Pass technology. The ECG is sent through the high-pass ﬁlter and through several noise and
double detection algorithms for accurate sensing of the QRS complex. The wide-band ECG is continuously used for rhythm discrimination. ECG5 electrocardio-
gram; S-ICD 5 subcutaneous implantable cardioverter-deﬁbrillator.
Table 1 Patient demographic characteristics and programming of the devices
Variable SMART Pass ON (n 5 655) SMART Pass OFF (n 5 1329) P
Age (y) 48 6 16 48 6 17 .76
Implanted model of the S-ICD
EMBLEM A209 253 (39) 1155 (87) ,.001
EMBLEM-MRI A219 402 (61) 174 (13)
Detection parameters (beats/min)
Dual-zone conﬁguration 631 (96) 1249 (94) .04
Conditional zone 200 (200–210) 200 (200–220) .04
Shock zone 240 (230–250) 240 (230–250) .62
Single-zone conﬁguration 24 (4) 78 (6) .04
Shock zone 230 (222–250) 230 (220–240) .20
Values are presented as mean 6 SD, as median (interquartile range), or as n (%).
S-ICD 5 subcutaneous implantable cardioverter-deﬁbrillator.
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therapy for the 706 episodes are presented in Table 2. A total
of 54Q16 % of treated episodes were classiﬁed as inappropriate
and 46% as appropriate.
Inappropriate shocks
The Kaplan-Meier curves illustrating time to ﬁrst inappropriate
shock as programmed are shown in Figure 2. At 1-year follow-
up, the inappropriate shock rateQ17 was lower for patients with SP
enabled than for those with SP disabled (4.3% vs 9.7%;
P , .001). The risk of the ﬁrst and recurrent inappropriate
shocks with SP as time-dependent variable is shown in
Figure 3. Patients with SP enabled had a 50% reduction of
the ﬁrst inappropriately treated episode (HR 0.50; 95% CI
0.37–0.68;P, .001) and the overall reduction of inappropriate
shocks was 68% (HR 0.32; 95% CI 0.22–0.47; P, .001). The
cumulative incidence of recurrent inappropriate shocks per 100
patient-years is presented in Figure 4.
The causes of the 380 inappropriately treated episodes
were SVT/AF above the discrimination zone (7%), SVT/AF
discrimination error (7%), cardiac oversensing (63%), and
noncardiac oversensing (22%). In the 241 episodes due to car-
diac oversensing, the main causes were low-amplitude sig-
nals (49%) and T-wave oversensing (47%). The effect of
SP enabled vs disabled on the different causes for the ﬁrst
inappropriate shock is presented in Figure 5. Inappropriate
shocks due to cardiac oversensing were lower for SP enabled
than for SP disabled (1.6% vs 6.4%; P , .001). Shocks for
AF/SVT/ST without oversensing occurred in 2.3% for SP
enabled vs 1.1% for SP disabled (P 5 .07). However, when
cardiac oversensing was the cause of inappropriate shocks,
the underlying rhythm was more often AF/SVT/ST for SP
disabled vs SP enabled (4.2% vs 0.5%; P , .001).
Table 2 Rhythm leading to ﬁrst appropriate and inappropriate
shocksQ20
Category
Appropriate
(n 5 326)
Inappropriate
(n 5 380)
Total
(n 5 706)
AF 19 (5) 19 (3)
Cardiac OS 258 (68) 258 (37)
MVT 174 (53) 174 (25)
Noncardiac OS 67 (17) 67 (9)
PVT/VF 152 (47) 152 (21)
ST 3 (1) 3 (0)
SVT 33 (9) 33 (5)
Values are presented as n (%).
AF 5 atrial ﬁbrillation/ﬂutter; MVT 5 monomorphic ventricular tachy-
cardia; OS 5 oversensing; PVT 5 polymorphic ventricular tachycardia;
ST5 sinus tachycardia; SVT5 supraventricular tachycardia; VF5 ventricular
ﬁbrillation.
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Figure 2 Incidence of the ﬁrst inappropriate shock stratiﬁed by SMART Pass enabled vs disabled Q22.
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Appropriate shocks
A total of 147 patients (7.4%) had 326 appropriately treated
ventricular tachyarrhythmias and were primarily discrete
events in unique patients. Therewere 152 PVT orVF episodes
in 74 patients and 174MVT episodes in 83 patients. At 1-year
follow-up, the cumulative incidence of appropriate shocks
was similar for patients with SP enabled and those with SP
disabled (5.2% vs 6.6%; P5 .21). In order to assess the effect
of SP on the detection of VF, PVT, and MVT, we analyzed
time to therapy and conversion efﬁcacy. No differences in
time to therapy were identiﬁed: 17.4 seconds (range, 14.6–
20.1 seconds) for SP enabled vs 16.7 seconds (range, 15.0–
20.9 seconds) for SP disabled (P 5 .92).
During the ﬁrst year of follow-up, 623 patients with SP
disabled (47%) crossed over to SP enabled and 78 patients
with SP enabled (12%) had at least 1 crossover programming.
When no censoring is used, regardless of subsequent pro-
gramming changes, the 1-year inappropriate shock incidence
at baseline was 5.9% for SP enabled and 9.2% for SP disabled
(P 5 .03) and the incidence of appropriate shocks was 5.2%
Figure 3 Forest plot illustrating the effect of SMART Pass on the risk of the ﬁrst and recurrent inappropriate shocks. CI 5 conﬁdence interval.
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Figure 4 Cumulative incidence of recurrent inappropriate shocks per 100 patient-years stratiﬁed by SMART Pass enabled vs disabled.
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and 7.1%, respectively (P5 .10). In patients with SP enabled
at implantation and consistently enabled during follow-up,
the 1-year inappropriate shock rate was 3.7% vs 9.9%
without SP consistently enabled (P , .0001) and the appro-
priate shock incidence was 5.3% vs 6.9% (P 5 .12).
Discussion
Main ﬁndings
This prospective evaluation of the effect of the high-pass ﬁl-
ter in a real-world patient group implanted with an S-ICD
yields several important ﬁndings. First, in patients in whom
a high-pass ﬁlter is activated there is a large reduction of inap-
propriate therapy for oversensing, both in the proportion of
patients with inappropriate shocks and in the total number
of inappropriate shocks delivered to those patients. Second,
the 1-year inappropriate shock rate is in line with rates
observed in the single-chamber transvenous ICD study using
therapy reduction programming strategies. Third, the rate of
appropriate therapy was not different between the group with
the high-pass ﬁlter enabled and the group with the high-pass
ﬁlter disabled. Regarding the safety of using this ﬁlter, the
time from arrhythmia onset to appropriate shock delivery
did not differ between the SP groups.
Inappropriate therapies
Previous studies such as the Evaluation oF Factors ImpacT-
ing CLinical Outcome and Cost EffectiveneSS of the S-ICD
study and the S-ICD Investigational Device Exemption trial
have reported inappropriate shock rates higher than those
observed in contemporary transvenous ICD studies.9,10 The
overall inappropriate shock rate for the S-ICD system has
been reported as 13% at 3-year follow-up.9 Most of these
shocks were due to oversensing of the cardiac signal, partic-
ularly oversensing of the T wave. The rates of inappropriate
shocks due to cardiac oversensing are reported as 5.2%–8.1%
on a per-patient basis at 11- to 12-month follow-up.7,11
Previous improvements to the discrimination algorithm
attempted to reduce this phenomenon, but were unable to
address it sufﬁciently. With the introduction of the latest
generation of the S-ICD, a new high-pass ﬁlter has become
available that selectively ﬁlters the T-wave frequency. The
reduction of inappropriate shocks aligns with previous
benchmark testing of the ﬁlter on stored episodes, where a
74% reduction of inappropriate shocks was observed.13
Often the inappropriate shock rate of the S-ICD is compared
against the 2% inappropriate shock rate observed inMulticenter
Automatic Deﬁbrillator Implantation Trial –Reduction in Inap-
propriate Therapy.14 However, when comparing inappropriate
shock rates across studies, it is important to consider both the
implanted devices and the clinical characteristics of the popula-
tion studied. A subanalysis of Multicenter Automatic Deﬁbril-
lator Implantation Trial – Reduction in Inappropriate Therapy
demonstrated that cardiac resynchronization patients and older
patients, who accounted for 50% of the trial population, experi-
enced half as many inappropriate shocks as ICD patients and
younger patients.15 The S-ICD is often selected in young and
active patients, as is also the case in the present cohort with a
mean age of 48 years. A recent meta-analysis of matched
studies of transvenous vs S-ICD therapywith balanced baseline
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Figure 5 Distribution of causes of the ﬁrst inappropriate shock by SMART Pass enabled vs disabled. AF/SVT/Sinus Tach5 atrial ﬁbrillation/supraventricular
tachycardia/sinus tachycardia; OS 5 oversensing.
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characteristics such as age and diagnosis did not ﬁnd a signiﬁ-
cantly higher inappropriate shock rate in S-ICD patients.16
However, it did demonstrate that the etiology of inappropriate
shocks is different between the devices, as in transvenous
ICDs most were caused by SVT discrimination errors whereas
oversensing was the main cause in S-ICDs.
The recently published subanalysis of the Avoid Deliv-
ering Therapies for Nonsustained Arrhythmias in ICD Pa-
tients III trial in single-chamber ICD patients demonstrated
that in the therapy reduction programming intervention arm
(30/40 NIDQ18 ), the inappropriate shock rate was 4.8% at
1-year follow-up.17 The 1-year inappropriate shock rate of
4.3% in the SP enabled group observed in our study is in
line with the rate observed in the Avoid Delivering Therapies
for Nonsustained Arrhythmias in ICD Patients III trial. In
addition, a subanalysis of the Pain Free Smart Shock Tech-
nology study of single-chamber devices found a 2.5% inap-
propriate shock rate at 1-year follow-up.18 The low
inappropriate shock rate observed in this study could not be
explained in a recent meta-analysis comparing 16 studies of
single-chamber transvenous ICDs and S-ICDs reporting on
inappropriate shocks.19 This comprehensive review of
studies found an annual inappropriate shock rate of 6.4% in
patients with a single-chamber device, with a tendency
toward a lower rate in the most recent years. The tendency to-
ward a lower inappropriate shock rate is conﬁrmed by our
study, as continuous improvement of technology reduced
the annual inappropriate shock rate from 8.1% as observed
in the Evaluation oF Factors ImpacTing CLinical Outcome
and Cost EffectiveneSS of the S-ICD study to 4.3% in the
present study in patients with SP enabled.11
Appropriate therapies
The appropriate shock rate in patients with SP enabled was
numerically lower, but did not reach statistical signiﬁcance.
Also, the time from the onset of ventricular arrhythmia until
delivery of the appropriate shock did not differ. Both these
ﬁndings suggest that the ﬁlter does not compromise the detec-
tion of ventricular arrhythmias or time to therapy. Impor-
tantly, the appropriate shock rate was similar to the rate
recently reported by Auricchio et al19 in a systematic review
and meta-analysis. Within a subgroup of the 16 studies that
reported appropriate shocks, 7 studies with 31,336 patients
followed for 6631 patient-years were included. Three of these
studies were of S-ICDs. The annualized appropriate shock
rate was estimated at 5.8% (95% CI 5.3%–6.3%), which is
similar to the rate observed in our study.
Study limitations
This study has several limitations. The study was not a ran-
domized trial comparing 2 treatment strategies and relies
on physician-directed programming. As programming could
change during follow-up, patients were evaluated as pro-
grammed in order to determine programming associated
with inappropriate shocks and sensitivity to VT/VF. All
shock episodes were systematically collected using the
remote monitoring system, which essentially eliminates the
chance of underreporting. LATITUDE allows for limited
demographic data; therefore, limited baseline characteristics
and no mortality data are available.
Conclusion
This prospective blinded evaluation of the SP ﬁlter demon-
strates that enabling the SP ﬁlter results in a signiﬁcant reduc-
tion of inappropriate shocks by the S-ICD without a negative
effect on appropriate shocks.
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